# OnCo record eortc-22033 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/eortc-22033/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "eortc-22033", "NCT00182819" ;
  schema:name "EORTC 22033-26033"@en ;
  schema:description "EORTC 22033 asked whether temozolomide could replace radiotherapy as the first treatment for high-risk low-grade glioma and found no difference in progression-free survival, with the molecular subtype mattering more than the choice of treatment."@en ;
  schema:url <https://onco.cc/trials/eortc-22033/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00182819>, <https://doi.org/10.1016/S1470-2045(16)30313-8> ;
  onco:status "negative" ;
  onco:tag "radiation-wave4" ;
  onco:phase "3" ;
  schema:startDate "2005-07" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/brain-tumours/>, <https://onco.cc/cancers/idh-mutant-astrocytoma/>, <https://onco.cc/cancers/oligodendroglioma/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/curie-nki-eortc/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-baumert-lancet-oncol/> .